Checkpoint Therapeutics Inc (NASDAQ:CKPT) has earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1-year consensus target price of $15.50 for the company and are expecting that the company will post ($0.35) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Checkpoint Therapeutics an industry rank of 154 out of 255 based on the ratings given to related companies.
Several brokerages recently commented on CKPT. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Checkpoint Therapeutics in a research note on Friday, May 11th. ValuEngine upgraded shares of Checkpoint Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Finally, Zacks Investment Research upgraded shares of Checkpoint Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Thursday, March 29th.
An institutional investor recently bought a new position in Checkpoint Therapeutics stock. Millennium Management LLC purchased a new position in shares of Checkpoint Therapeutics Inc (NASDAQ:CKPT) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 75,390 shares of the company’s stock, valued at approximately $331,000. Millennium Management LLC owned approximately 0.24% of Checkpoint Therapeutics at the end of the most recent reporting period. 1.47% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CKPT traded up $0.19 during midday trading on Tuesday, reaching $2.98. The stock had a trading volume of 55,900 shares, compared to its average volume of 66,719. Checkpoint Therapeutics has a 1-year low of $2.25 and a 1-year high of $10.50. The firm has a market capitalization of $93.16 million and a price-to-earnings ratio of -2.98.
Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings data on Thursday, May 10th. The company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.13). Checkpoint Therapeutics had a negative net margin of 1,967.93% and a negative return on equity of 122.20%. The firm had revenue of $0.34 million during the quarter. equities research analysts expect that Checkpoint Therapeutics will post -1.36 EPS for the current year.
Checkpoint Therapeutics Company Profile
Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC.
Get a free copy of the Zacks research report on Checkpoint Therapeutics (CKPT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.